|Mr. Alan Thomas Hirzel BS, MS, MBA||CEO & Exec. Director||1.19M||N/A||1968|
|Dr. Jonathan Simon Milner||Co-Founder & Non-Exec. Deputy Chairman||70k||N/A||1965|
|Mr. Michael Shaun Baldock||CFO & Director||N/A||N/A||1964|
|Mr. Mark Dermody||Interim CIO||N/A||N/A||N/A|
|James Staveley||VP of Investor Relations||N/A||N/A||N/A|
Abcam plc, a life sciences company, researches, develops, and distributes biological reagents and tools for research, drug discovery, and diagnostics in the United States, China, Japan, Germany, the United Kingdom, and internationally. The company offers various research products, including primary and secondary antibodies; ELISA and matched antibody pairs; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex assays. Its research products are used in the areas of cancer, cardiovascular, cell biology, developmental biology, epigenetics, nuclear signaling, immunology, metabolism, microbiology, neuroscience, signal transduction, and stem cells. The company also offers diagnostic and therapeutic solutions. The company also sells its products online. Abcam plc was founded in 1998 and is headquartered in Cambridge, the United Kingdom.
Abcam plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.